Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
China · Delayed Price · Currency is CNY 107.03
-6.81 (-5.98%)
May 12, 2026, 3:00 PM CST
Beijing Hotgen Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 427.66 | 404.88 | 505.01 | 544.62 | 3,532 | 5,307 |
Other Revenue | - | - | 5.89 | 3.22 | 24.41 | 62.65 |
| 427.66 | 404.88 | 510.9 | 547.84 | 3,557 | 5,369 | |
Revenue Growth (YoY) | -12.16% | -20.75% | -6.74% | -84.60% | -33.76% | 945.54% |
Cost of Revenue | 172.54 | 171.78 | 257.18 | 211.72 | 1,766 | 2,254 |
Gross Profit | 255.13 | 233.09 | 253.72 | 336.11 | 1,790 | 3,116 |
Selling, General & Admin | 356.33 | 328.68 | 289.77 | 258.6 | 483.58 | 404.26 |
Research & Development | 190.46 | 162.28 | 113.31 | 132.88 | 191.14 | 131.92 |
Other Operating Expenses | -9.49 | -8.4 | 3.45 | 3.58 | 9.2 | 5.04 |
Operating Expenses | 537.09 | 482.56 | 407.9 | 381.66 | 695.26 | 541.92 |
Operating Income | -281.96 | -249.47 | -154.18 | -45.55 | 1,095 | 2,574 |
Interest Expense | - | - | -0.45 | -1.01 | -2.32 | -1.27 |
Interest & Investment Income | 35.57 | 60.67 | 32.85 | 39.59 | 34.52 | 34.26 |
Currency Exchange Gain (Loss) | - | - | -0.78 | 4.31 | 4.95 | -14.64 |
Other Non Operating Income (Expenses) | -1.19 | 2.14 | 0.24 | -1.27 | 3.31 | -4.82 |
EBT Excluding Unusual Items | -247.58 | -186.66 | -122.32 | -3.92 | 1,135 | 2,587 |
Gain (Loss) on Sale of Investments | -27.57 | -37.76 | -9.36 | -23.68 | 7.52 | 3.12 |
Gain (Loss) on Sale of Assets | 0.37 | 0.58 | -1.63 | -0.64 | -0.34 | -14.21 |
Asset Writedown | -31.96 | -43.43 | -60.85 | -41.79 | -70.06 | -8.51 |
Other Unusual Items | - | - | 6.29 | 85.02 | 2.63 | 14.22 |
Pretax Income | -306.74 | -267.28 | -187.87 | 14.99 | 1,075 | 2,582 |
Income Tax Expense | -9.19 | -8.64 | 8.06 | -1.73 | 150.1 | 379.44 |
Earnings From Continuing Operations | -297.56 | -258.63 | -195.94 | 16.71 | 925.12 | 2,202 |
Minority Interest in Earnings | 50.85 | 42.59 | 4.93 | 12.21 | 19.62 | -16.61 |
Net Income | -246.7 | -216.05 | -191 | 28.92 | 944.74 | 2,186 |
Net Income to Common | -246.7 | -216.05 | -191 | 28.92 | 944.74 | 2,186 |
Net Income Growth | - | - | - | -96.94% | -56.78% | 1850.41% |
Shares Outstanding (Basic) | 87 | 86 | 92 | 88 | 91 | 92 |
Shares Outstanding (Diluted) | 87 | 86 | 92 | 88 | 92 | 92 |
Shares Change (YoY) | -1.25% | -6.46% | 4.59% | -3.88% | -0.14% | -0.12% |
EPS (Basic) | -2.84 | -2.50 | -2.07 | 0.33 | 10.33 | 23.75 |
EPS (Diluted) | -2.84 | -2.50 | -2.07 | 0.33 | 10.28 | 23.75 |
EPS Growth | - | - | - | -96.81% | -56.72% | 1852.80% |
Free Cash Flow | -189.86 | -126.93 | -88.57 | -461.9 | 413.54 | 2,246 |
Free Cash Flow Per Share | -2.19 | -1.47 | -0.96 | -5.23 | 4.50 | 24.40 |
Dividend Per Share | - | - | - | 0.200 | - | 3.378 |
Dividend Growth | - | - | - | - | - | 233.34% |
Gross Margin | 59.66% | 57.57% | 49.66% | 61.35% | 50.34% | 58.03% |
Operating Margin | -65.93% | -61.62% | -30.18% | -8.31% | 30.79% | 47.93% |
Profit Margin | -57.69% | -53.36% | -37.39% | 5.28% | 26.56% | 40.71% |
Free Cash Flow Margin | -44.40% | -31.35% | -17.34% | -84.31% | 11.63% | 41.82% |
EBITDA | -201.23 | -168.02 | -69.84 | 15.66 | 1,184 | 2,631 |
EBITDA Margin | -47.05% | -41.50% | -13.67% | 2.86% | 33.30% | 49.00% |
D&A For EBITDA | 80.73 | 81.45 | 84.33 | 61.2 | 89.39 | 57.5 |
EBIT | -281.96 | -249.47 | -154.18 | -45.55 | 1,095 | 2,574 |
EBIT Margin | -65.93% | -61.62% | -30.18% | -8.31% | 30.79% | 47.93% |
Effective Tax Rate | - | - | - | - | 13.96% | 14.70% |
Revenue as Reported | 22.79 | - | 510.9 | 547.84 | 3,557 | 5,369 |
Advertising Expenses | - | - | 15.59 | 13.38 | 55.08 | 68.41 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.